Thevis Mario, Koch Anja, Sigmund Gerd, Thomas Andreas, Schänzer Wilhelm
Institute of Biochemistry, Center for Preventive Doping Research, German Sport University Cologne, Am Sportpark Müngersdorf 6, 50933 Cologne, Germany.
Biomed Chromatogr. 2012 May;26(5):610-5. doi: 10.1002/bmc.1705. Epub 2011 Sep 19.
The biogenic amine octopamine [4-(2-amino-1-hydroxyethyl)phenol] is prohibited in sports owing to its stimulating and performance-enhancing properties. Adverse analytical findings in athletes' doping control samples commonly result from surreptitious applications; however, the occurrence of octopamine in nutritional supplements and in selected invertebrates as well as the assumption that its N-methylated analog synephrine [4-(1-hydroxyethyl-2-methylamino)phenol, not banned by anti-doping authorities but currently monitored in prevalence studies) might be converted in-vivo into octopamine have necessitated a study to investigate the elimination of synephrine and octopamine present in over-the-counter products. Urine samples collected after administration of nutritional supplements containing octopamine and/or synephrine as well as urine samples collected after therapeutic application of octopamine- or synephrine-containing drugs were analyzed using a validated solid-phase extraction-based procedure employing a weak cation exchange resin and liquid chromatographic/tandem mass spectrometric detection with electrospray ionization and multiple reaction monitoring. In the case of therapeutic octopamine application, the urinary concentration of the target compound increased from baseline levels below the lower limit of detection to 142 µg/mL, while urine samples collected after synephrine as well as dietary supplement administration did not yield any evidence for elevated renal excretion of octopamine.
生物胺章鱼胺[4-(2-氨基-1-羟乙基)苯酚]因其具有刺激和增强体能的特性而在体育运动中被禁用。运动员兴奋剂检测样本中的不良分析结果通常源于偷偷使用；然而，营养补充剂和某些无脊椎动物中存在章鱼胺，以及其N-甲基化类似物辛弗林[4-(1-羟乙基-2-甲氨基)苯酚，未被反兴奋剂机构禁止但目前在流行率研究中受到监测]可能在体内转化为章鱼胺的假设，使得有必要开展一项研究来调查非处方产品中存在的辛弗林和章鱼胺的消除情况。使用经过验证的基于弱阳离子交换树脂的固相萃取程序以及采用电喷雾电离和多反应监测的液相色谱/串联质谱检测法，对服用含有章鱼胺和/或辛弗林的营养补充剂后收集的尿液样本以及使用含章鱼胺或辛弗林药物进行治疗后收集的尿液样本进行了分析。在治疗性使用章鱼胺的情况下，目标化合物的尿液浓度从低于检测下限的基线水平增加到142μg/mL，而服用辛弗林以及膳食补充剂后收集的尿液样本未提供任何证据表明章鱼胺的肾脏排泄增加。
